[go: up one dir, main page]

WO2018141313A3 - Uses of fgf-4 compounds - Google Patents

Uses of fgf-4 compounds Download PDF

Info

Publication number
WO2018141313A3
WO2018141313A3 PCT/CN2018/083256 CN2018083256W WO2018141313A3 WO 2018141313 A3 WO2018141313 A3 WO 2018141313A3 CN 2018083256 W CN2018083256 W CN 2018083256W WO 2018141313 A3 WO2018141313 A3 WO 2018141313A3
Authority
WO
WIPO (PCT)
Prior art keywords
fgf
compounds
relates
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2018/083256
Other languages
French (fr)
Other versions
WO2018141313A9 (en
WO2018141313A2 (en
Inventor
Hao Wu
Zhe Wang
Dan HAN
Fang Zhang
Xiaoli Chen
Rasmus Joergensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to PCT/CN2018/083256 priority Critical patent/WO2018141313A2/en
Publication of WO2018141313A2 publication Critical patent/WO2018141313A2/en
Publication of WO2018141313A9 publication Critical patent/WO2018141313A9/en
Publication of WO2018141313A3 publication Critical patent/WO2018141313A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne les utilisations de composés FGF-4. De manière plus spécifique, l'invention porte sur les utilisations de composés FGF-4 dans la prévention et/ou le traitement de troubles du métabolisme.The present invention relates to the uses of FGF-4 compounds. More specifically, the invention relates to the uses of FGF-4 compounds in the prevention and / or treatment of metabolic disorders.

PCT/CN2018/083256 2018-04-17 2018-04-17 Uses of fgf-4 compounds Ceased WO2018141313A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/083256 WO2018141313A2 (en) 2018-04-17 2018-04-17 Uses of fgf-4 compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/083256 WO2018141313A2 (en) 2018-04-17 2018-04-17 Uses of fgf-4 compounds

Publications (3)

Publication Number Publication Date
WO2018141313A2 WO2018141313A2 (en) 2018-08-09
WO2018141313A9 WO2018141313A9 (en) 2018-09-07
WO2018141313A3 true WO2018141313A3 (en) 2019-02-21

Family

ID=63039362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/083256 Ceased WO2018141313A2 (en) 2018-04-17 2018-04-17 Uses of fgf-4 compounds

Country Status (1)

Country Link
WO (1) WO2018141313A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111944035B (en) * 2019-05-14 2022-08-12 温州医科大学 FGF4 and its applications
CN115991762B (en) * 2022-08-24 2025-08-29 温州医科大学 Recombinant human FGF4 protein and its application in skin wound repair

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012053A2 (en) * 2001-08-01 2003-02-13 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis
WO2011158125A2 (en) * 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
CN102971001A (en) * 2009-08-14 2013-03-13 阿勒根公司 Methods of treating cancer using growth factor retargeted endopeptidases
KR101490017B1 (en) * 2013-03-14 2015-02-09 건국대학교 산학협력단 Medium Composition for Establishing Novel Epiblast Stem Cell and Method for Establishing Novel Epiblast Stem Cell Using Thereof
WO2015171928A2 (en) * 2014-05-07 2015-11-12 Joslin Diabetes Center, Inc. Methods and compositions for induction of ucp1 expression

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012053A2 (en) * 2001-08-01 2003-02-13 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis
CN102971001A (en) * 2009-08-14 2013-03-13 阿勒根公司 Methods of treating cancer using growth factor retargeted endopeptidases
WO2011158125A2 (en) * 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
KR101490017B1 (en) * 2013-03-14 2015-02-09 건국대학교 산학협력단 Medium Composition for Establishing Novel Epiblast Stem Cell and Method for Establishing Novel Epiblast Stem Cell Using Thereof
WO2015171928A2 (en) * 2014-05-07 2015-11-12 Joslin Diabetes Center, Inc. Methods and compositions for induction of ucp1 expression

Also Published As

Publication number Publication date
WO2018141313A9 (en) 2018-09-07
WO2018141313A2 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
MA64509B1 (en) HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
MA64121B1 (en) HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
MA57825B1 (en) SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS
MA53937B1 (en) Compositions comprising bacterial strains
MA52288B1 (en) METHYL-MODIFYING ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF
MA54231A (en) 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN
MA42279A (en) COMPOSITIONS INCLUDING A BACTERIAL STRAIN OF BLAUTIA HYDROGENOTROPHICA FOR USE FOR THE PREVENTION OR TREATMENT OF DIARRHEA OR CONSTIPATION
MA40290A1 (en) Immune-regulating agents
MA47043A1 (en) Indole carboxamide compounds useful as kinase inhibitors
WO2019209962A8 (en) Compounds and uses thereof
MA43113A (en) ANTI-HTR A1 ANTIBODIES AND METHODS OF USING THEM
MA45598B1 (en) 24-hydroxy steroles substituted in position 11 for the treatment of diseases linked to the nmda receptor
EA202192047A1 (en) COMPOUNDS AND THEIR APPLICATIONS
MA30485B1 (en) AMINOTHIAZOLES AND USES THEREOF
FR3084255B1 (en) STREPTOCOCCUS THERMOPHILUS CNRZ160 STRAIN FOR THE TREATMENT AND PREVENTION OF BOWEL INFLAMMATION AND RELATED DISORDERS IN AN INDIVIDUAL
MA62935B1 (en) METHODS OF TREATMENT OR PREVENTION OF SPINAL AMYOTROPHY
WO2018141313A3 (en) Uses of fgf-4 compounds
FR3063905B1 (en) USE OF COPAIFERA IN COSMETICS AND DERMATOLOGY
MA56998B1 (en) TREATMENT OF SYMPTOMS INDUCED BY THE MENSTRUAL CYCLE
PH12022552499A1 (en) Technologies for preventing or treating infections
MA31562B1 (en) MACROCYCLES AND THEIR USES
EP3344071A4 (en) COMBINED COMPOSITIONS FOR REGULATING GLYCEMIA LEVELS, HEPATOPROTECTION, AND FOR THE PREVENTION AND TREATMENT OF ASSOCIATED MEDICAL CONDITIONS
FR2938429B1 (en) COSMETIC USE OF MICROORGANISM (S) FOR THE TREATMENT OF SKIN LEATHER DISORDERS
MA44660B1 (en) (+) -AZASETRON FOR ITS USE IN THE TREATMENT OF EAR DISORDERS
EP4159214A4 (en) COMPOSITION FOR THE TREATMENT, IMPROVEMENT AND/OR PREVENTION OF THE PROGRESSION OF BOVINE PAPILLOMATOSIS CAUSED BY BOVINE PAPILLOMAVIRUS

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18747641

Country of ref document: EP

Kind code of ref document: A2